Background. Radiofrequency ablation (RFA) use among patients with hepatocellular carcinoma (HCC) has increased dramatically over the last decade, but assessments outside specialized centers are lacking. This population-based study was intended to evaluate the safety and effectiveness of RFA when used to treat HCC. Methods. A cohort study of HCC patients (diagnosed 2002-2005) was performed using linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Early (B90-day) mortality and readmission as well as survival among patients undergoing RFA, resection, or no treatment were compared using multivariate and propensity score adjusted Poisson and Cox regression models. Results. Of 2631 patients (mean age 76.1 ± 6.1 years, 65.9% male), 16% underwent RFA (49.6%) or resection (50.4%). Early mortality (13.6 vs. 18.7%, P = .16) and readmission (34.5 vs. 32.1%, P = .60) rates were similar among RFA and resection patients. The 1-year survival after RFA and resection was similar (72.2 vs. 79.7%, P = .18), but beyond 3 years there was a survival benefit among patients undergoing resection (39.2 vs. 58.0%, P \ .001). Patients treated with RFA as a sole therapeutic intervention in the 1st year had a similar hazard of death compared with untreated patients (hazard ratio [HR] 0.84, 95% confidence interval [95% CI] 0.54-1.33). Conclusions. In the general community, patients treated with RFA have a similar risk of early adverse events compared with those treated with resection with no clear survival benefit when used as a sole intervention. Although RFA has been described as a safe and effective treatment for HCC at specialized centers, this experience may not extrapolate to the general community and requires further evaluation.
In the United States, radiofrequency ablation (RFA) use among patients with hepatocellular carcinoma (HCC) has increased dramatically. 1 While general indications for RFA have been described (3 or fewer B3-cm lesions or a solitary lesion B5 cm), little data define patients for whom RFA is most appropriate, those who stand to benefit from RFA treatment, and possible reasons to deviate from current indications. 2 Numerous case series report results among many patient subgroups (potentially resectable, cirrhotics, etc.); however, questions regarding generalizability to the general community remain because outcomes from specialized centers may not necessarily translate to community practice. Although RFA is widely perceived as safe and effective based on these studies, this hypothesis has not been rigorously evaluated in a population-based fashion.
The goals of this study were 2-fold. First, identify whether RFA can be performed in the general community with a low rate of early adverse events. If so, early adverse event rates after RFA should be lower compared to resection. Second, evaluate whether RFA performed in the general community represents an effective HCC treatment. If so, there should be a survival advantage among patients treated with RFA compared to untreated patients. To address these issues of comparative effectiveness, we performed a population-based assessment of safety and effectiveness among patients with HCC who underwent RFA, resection, or no treatment.
METHODS

Data
A cohort study of patients diagnosed with HCC between 2002 and 2005 was conducted using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. A comprehensive discussion of the content, quality, and generalizability of SEER-Medicare data has been detailed previously. [3] [4] [5] This study was approved by the University of Washington Institutional Review Board and the National Cancer Institute. The National Cancer Institute reviews all manuscripts submitted for peer review to ensure confidentiality for all patients and practitioners contained within the database-this manuscript was approved April 22, 2010.
Study Subjects
From SEER records, we identified 10,350 patients with an incident HCC diagnosis. Sequential exclusions were then made for: diagnosed by autopsy/death certificate (n = 493), histology inconsistent with HCC (n = 1747 [ICD-O-3 codes other than 8170-8175 were excluded]), age \66 years (n = 2445), second malignancy diagnosed within 6 months prior to or after the HCC diagnosis (n = 66), concurrently enrolled in an HMO and/or not continuously fee-for-service for 1 year before and 3 months after diagnosis (n = 2866), underwent one or more additional therapeutic interventions potentially attributable to the HCC diagnosis in the time period between diagnosis and their index procedure or no treatment (n = 39), underwent a liver transplant any time after diagnosis (n = 63). This gave a final cohort of 2631 patients. The exclusion of patients younger than 66 years was to enhance the generalizability of our findings since nonelderly patients enrolled in Medicare are either disabled, have end-stage renal disease, or both. Since RFA or hepatic resection can be used in the treatment of liver lesions other than HCC, patients with a second malignancy were excluded. Patients not entirely feefor-service were excluded since concurrent enrollment in another insurance program may lead to incomplete claims ascertainment. To avoid confusing the effectiveness of either resection or RFA with that of other interventions, patients who received additional therapeutic interventions prior to the index procedure were excluded. Patients undergoing transplant could have biased the analysis (since it is the treatment of choice for HCC) and were excluded.
Variables
Demographic and clinical information was available through SEER records. A Klabunde-modified Charlson comorbidity index was calculated from the Physician/ Carrier and Outpatient claims files in the year prior to diagnosis. 6 Included within the Charlson index is a combination of diagnostic and procedural codes characterizing the severity of a patient's liver-associated comorbid condition. Because we were concerned about the possibility of residual confounding, we searched for diagnostic codes (not already included in the Charlson) from the year prior to diagnosis in the Physician/Carrier, Outpatient, and MEDPAR files that might potentially be associated with the severity of a patient's liver-associated comorbidity and/ or play a role in treatment decisions: ascites (789. 5 4, 277.4) , and other cirrhotic liver conditions (571.5, 571.8, 571.9). These were then used to construct propensity scores for the three treatment groups that were subsequently used to adjust the regression analyses. Indicators of low income and low education were based on the lowest quartile of median income and the proportion without a high-school education within a given zip code, respectively. Healthcare Common Procedure Coding System (HCPCS) in the Physician/Carrier file within 3 months after diagnosis were used to define RFA (47382, 47370, 47380) and resection (47122, 47125, 47120, 47130). HCPCS from the Outpatient file within 3 months after diagnosis were also used to ascertain RFA use.
Analysis
This analysis included three study groups: those treated with resection, RFA, or untreated patients. Untreated patients were defined as those who did not undergo any therapeutic interventions (transplantation, resection, RFA, transarterial chemoembolization, or other forms of ablation) within 3 month after diagnosis. Statistical analyses were performed using STATA 10.1 (StataCorp, College Station, TX). All statistical comparisons were 2-sided and P values were considered significant at the P \ .05 level. Categorical and continuous comparisons were obtained using v 2 and analysis of variance, respectively. The log-rank test was used to assess differences in survival. Because this study included three comparison groups, propensity scores were calculated using multinomial logistic regression. 7 Balance of the propensity scores was graphically assessed, and the scores were deemed to be equally distributed among the three treatment groups. The propensity scores were subsequently stratified into quintiles. To deal with missing data, regression analyses were repeated using five sets of covariate data obtained through multiple imputation by chained equations. 8, 9 Ascertainment of death was possible through 2006 for all patients. Overall survival was the primary outcome. Secondary outcomes were early (\90 day) mortality and readmission assessed as binary variables. Time to death, readmission, or censoring was calculated as the lag between index procedure date or diagnosis date (for untreated patients) and outcome. For untreated patients and those who underwent outpatient RFA, ''readmission'' was defined as an inpatient admission after HCC diagnosis or after the outpatient procedure, respectively. Only patients in whom readmission could be ascertained (due to fee-forservice considerations) were included in the assessment of this outcome.
Associations between overall survival and treatment were evaluated using Cox proportional hazard regression. The proportional hazard assumption was assessed using Schoenfeld residuals and extended (stratified) models were used if this assumption was not satisfied. Because early mortality and readmission were common in this cohort, the use of logistic regression would likely have overestimated the association between treatment and outcome. Thus, Poisson regression was used to calculate adjusted risk ratios. [10] [11] [12] Analyses were also evaluated in subgroups who were continuously fee-for-service for 6 months postdiagnosis and those who were continuously fee-for-service for 1-year post diagnosis. These subgroups allowed evaluation of survival among patients not receiving other potentially therapeutic interventions (other than additional RFA sessions for those in the RFA group) after their index procedure-the intent being to capture only the effect of RFA or resection. All regression analyses used robust standard errors and covariate adjustments for age quartile at the time of diagnosis, sex, race, marital status, extent of disease (local, regional, distant), Charlson score, prior malignancy, tumor size (B2 cm, 2.1-5 cm, or [5 cm), [1 lesion, propensity score quintile, as well as clustering at the regional level.
RESULTS
There were 2,631 patients with a diagnosis of HCC (average age 76.1 ± 6.1 years, with 65.9% being male, and 67.9% white). Most patients (84.2%) were untreated, while 7.8% underwent RFA and 7.9% resection. Among treated patients, 39.7% had tumors [5 cm and 41.7% had more than 1 lesion. Most patients had some burden of comorbid illness, with 68.5% having a Charlson score C1. Table 2 describes the liver-related comorbid conditions used to generate the propensity scores and the distribution of these conditions across the three treatment groups.
Safety Assessment
The 30-day and 90-day mortality rates for the cohort were 1.5% and 21.6%, respectively. Although the rate of 30-day (5.3 vs. 10.1%, P = .08) and 90-day mortality (13.6 vs. 18.7%, P = .16) after RFA was lower than resection, neither comparison achieved statistical significance. Compared with untreated patients (0.5% and 22.6%; 30-day and 90-day mortality, respectively), RFA-treated patients had higher 30-day (P \ .001) and lower 90-day mortality (P = .005), while resected patients had higher 30-day (P \ .001) but similar 90-day mortality. Table 3 describes adjusted risk ratios associated with treatment and safety outcomes. Comparing resection and RFA, there were no identifiable differences in the risk of either early mortality or readmission.
Effectiveness Assessment
Overall survival rates at 1, 3, and 5 years for the cohort were 44.5%, 21.9%, and 17.4%, respectively. There was no difference in survival at 1 year between patients who underwent RFA and resection (72.2% vs. 79.7%, P = .18). However, at 3 years (39.2 vs. 58.0%, P \ .001) and 5 years (34.8 vs. 50.2%, P \ .001), survival after resection was significantly higher. 
Sensitivity Analyses
Sensitivity analyses were conducted to evaluate whether the results of the effectiveness assessment were robust to varying assumptions. Because these analyses did not vary greatly from our initial analysis, only a brief summary is As an exploratory analysis, the clinical characteristics of the small number of patients (n = 18) who survived at least 3 years after treatment with RFA were evaluated. Compared with RFA treated patients surviving less than 3 years, their clinical characteristics suggested they may have been a lower surgical risk group, had favorable tumor biology, and/or signs of social support: Charlson score of B1 (78 vs. 63%), no prior malignancies (89 vs. 72%), tumor size B5 cm (86 vs. 78%), married (78 vs. 66%). The majority of these patients also had favorable economic characteristics (all had higher levels of education and only 22% were low income).
DISCUSSION
In this population-based evaluation, we observed three important findings that should prompt further studies to clarify the role for RFA as a treatment for HCC patients in the general community. First, when compared with patients undergoing resection, the risk of early adverse events was not significantly lower among RFA-treated patients. Second, when RFA was used as the only therapeutic intervention (either in single or multiple sessions) in the 1st year after diagnosis, there was no obvious survival benefit over no treatment. Finally, RFA may be associated with some survival benefit for certain patient subgroups who as yet have not been well characterized.
In a prior population-based analysis, our group identified a several-fold increase in RFA use over the last decade with a large proportion of the patients treated with RFA having a dominant lesion [5 cm or multiple lesions at diagnosis. 1 Although general indications for RFA use exist and may vary between institutions, current data suggest RFA may be less effective for patients with lesions [5 cm and/or those with more than 1 lesion because of a high local recurrence rate. 13 This either suggests indications for RFA are not widely known or expanded indications are being applied in the absence of data to support such practice. Alternatively, patient demand for new therapeutic technologies, low associated cost for clinicians to learn to apply the technology, marketing/promotion by device manufacturers, and perceived benefits to stakeholders have been identified as important drivers of adoption of new surgical innovations-RFA satisfies each of these four conditions. 14 Complications and inpatient mortality rates after hepatic resection have been reported to be 40-50% and 5-6%, respectively. [15] [16] [17] [18] [19] By comparison, numerous studies have (14) 57 (28) 45 (22) Portal vein thrombosis 192 (7) 165 (8) 16 (8) 11 ( reported low rates of complications (1.8-10%) and perioperative death (B1%) after RFA. [20] [21] [22] [23] [24] [25] [26] [27] [28] In this cohort, we found a higher rate of early mortality than previously reported. Also, risk of early death and readmission after RFA was not different compared with resection. This suggests RFA may not be as safe as has been widely reported. Because prior studies were from Asia, Europe, and/or referral centers in the United States, outcomes from these centers may not be indicative of care provided in the community at large. By comparison, SEER-Medicare data are considered representative of care provided in the general community and across varied practice settings. 3 Alternatively, our results may simply represent RFA use among poorly selected and/or high-risk patients.
Two recent randomized trials have compared RFA with resection among patients within Milan criteria. The first demonstrated no significant difference in either overall or disease-free survival. 29 There were, however, numerous issues pertaining to the study design and methods making interpretation of the results challenging (e.g., inconsistency between the sample size calculation [based on recurrence] and the reported endpoints [survival]; the authors concluding equivalence between RFA and resection even though a noninferiority design was not used [underpowering the study to assess equivalence]). In the second trial, the authors found significantly better overall and recurrence-free survival as well as lower recurrence rates among resection patients. 30 Our prior and current work suggest a notable proportion of U.S. patients treated with RFA fall outside Milan criteria; therefore, the generalizability of the results from this study must be considered. In our current study, RFA-treated patients not receiving any other form of intervention within 1 year of diagnosis did not have a significantly lower risk of death relative to no treatment. The sample size in these subgroups was relatively small (96 patients received a single RFA session and 126 patients underwent 1 or more RFA sessions); therefore, the analyses may have been underpowered to detect a survival benefit. However, our study also included a similar number of patients who underwent only resection (n = 139) that clearly demonstrated a benefit relative to both RFA and no treatment.
We expected to see a survival advantage attributable to RFA when compared with no treatment. The fact that we did not observe this either suggests RFA as a solitary intervention may not be as effective as previously described or more likely indicates poor patient selection (for example, when used outside of current indications or among patients who are at high surgical risk). Poor patient selection may have occurred (at least in part) because patients for whom RFA treatment is most appropriate have, as yet, not been well-defined. To explore this issue of selection, we evaluated the available characteristics of patients surviving at least 3 years and found they generally had favorable socioeconomic and clinical characteristicshighlighting the importance of patient selection in determining the effectiveness of RFA as an HCC treatment. While there may be a desire to offer RFA to any HCC patient not a candidate for resection or transplantation, improved survival may only occur among carefully selected surgical candidates.
These results must be interpreted in the context of several limitations. First, we were unable to ascertain intent or indication for RFA use. If RFAs were performed with curative intent (among potentially resectable patients), the lack of an obvious survival benefit relative to no treatment is not reassuring of RFA's effectiveness. Alternatively, it is possible none of the RFAs were intended as a stand-alone therapy. However, even when patients who underwent multiple RFA sessions were considered, risk of death was not different compared with no treatment. While some RFAs may have been intended as a bridge to   FIG. 1 Multivariate analysis of therapeutic effectiveness comparing a resection to no treatment (reference no treatment), b resection to RFA (reference RFA), c RFA to no treatment (reference no treatment). These subgroups did not undergo any other potentially therapeutic procedures within 6 months or 1 year of diagnosis, respectively. Similarly, untreated patients received no therapeutic interventions over this same time period. à These subgroups did not undergo any other potentially therapeutic procedures (except additional RFA sessions for those in the RFA group) within 6 months or 1 year of diagnosis, respectively. Similarly, untreated patients received no therapeutic interventions over this same time period. *P \ .05, § P \ .001 transplantation, the mean age of this cohort (well over 70 years) makes transplantation an unlikely anticipated endpoint.
Other limitations include restriction of our study to elderly, Medicare beneficiaries with full, fee-for-service coverage that could affect the generalizability of our results to broader patient populations. Although we controlled for comorbid illness using the Charlson score and the presence of additional liver-related comorbid conditions using propensity score adjustment, our results still likely suffer from residual confounding by indication. Since procedural ascertainment was based on HCPCS, our study included a relatively small sample of patients treated with RFA (because a CPT code for RFA was not created until 2002), potentially resulting in Type II error for some parts of the analysis (for example, to identify a statistically significant difference in 30-day and 90-day mortality of the observed magnitude with 80% power, 524 and 855 patients in each treatment group, respectively, would have been needed). Some patients may have been misclassified in terms of the readmission outcome-data on the indication for readmission are not provided, and it is not possible to ascertain whether a readmission was planned. Finally, SEER-Medicare data do not contain information on tumor location, variables quantifying surgical risk (e.g., cardiovascular status, preoperative and postoperative lab data, family involvement, as well as other pertinent surgical and anesthetic factors), or other clinical variables impacting surgical decision-making. Such information would have been helpful to understand therapeutic intent allowing a more accurate comparison of RFA and resections performed for the same purpose or to provide more adequate risk adjustment.
In this population-based evaluation, we were unable to identify an early safety benefit for RFA (compared with resection) or an obvious survival benefit when used as a lone therapeutic intervention (compared with no treatment). We did however identify a higher than anticipated rate of early mortality and readmission that should be factored into any informed consent discussion between a patient and his or her provider. The results of this work suggest a need for more data to inform on RFA use in the United States and highlight the importance of patient selection. Future work should attempt to identify patients for whom RFA use is most appropriate, better define the impact of liver reserve and/or burden of comorbid illness on RFA outcomes, and evaluate outcomes based on institutional/provider experience-all of which will be important for defining its role as a management option for patients with HCC.
